According to TipRanks, Souda is a 4-star analyst with an average return of 4.0% and a 44.76% success rate. Souda covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Illumina, and Revvity.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Revvity with a $110.25 average price target, representing a 0.09% upside. In a report released on July 15, TD Cowen also maintained a Buy rating on the stock with a $130.00 price target.
Based on Revvity’s latest earnings release for the quarter ending April 5, the company reported a quarterly revenue of $711.12 million and a net profit of $40.72 million. In comparison, last year the company earned a revenue of $664.76 million and had a net profit of $42.24 million
